Leica Biosystems Digital Pathology Solutions Offer Improved Image Quality and Flexible Scanning
Leica Biosystems enables researchers to accelerate their journey, transforming scientific exploration into translational outcomes, with a new digital pathology software release.
9 November 2023, VISTA, CA – Leica Biosystems, a global leader in pathology workflow solutions, is pleased to announce the release of three important software features for its proven Aperio GT 450 Digital Pathology scanner. The announcement took place at the Society for Immunotherapy of Cancer’s annual meeting, and visitors to the Leica Biosystems booth had the opportunity to experience the new features hands-on.
The Aperio GT 450 is a time-tested technology designed to support flexible scanning requirements and automated workflows, while delivering superior quality. The new enhancements, including a patent-pending quality control feature, will help to improve image quality and flexible scanning solutions in research settings: Z-Stack Scanning, Automatic Narrow Stripe Scanning and 20x Magnification:
- Z-Stack Scanning – Multiplane scanning that produces a composite, 3D image that enables research pathologists to review slide samples at varied levels of thickness, similar to a traditional microscope.
- Automatic Narrow Stripe Scanning – Quality control that enables an automatic rescan of a slide when the system detects image quality issues resulting from a tilted slide or tilted tissue.
- 20x Magnification – an important solution for saving space if 40x is not needed
“Digital pathology offers a significant advantage for laboratory scientists in cancer research. The growing amount of research performed will be empowered by the accessibility and efficiencies afforded by this technology,” said Naveen Chandra, Vice President of Digital Pathology at Leica Biosystems. “We aim to shape the future with novel technologies that inspire every researcher’s exploration of biology.”
About Leica Biosystems:
Leica Biosystems is a cancer diagnostics company and a global leader in workflow solutions. The company offers a comprehensive product range for each step in the pathology process, from sample preparation and staining to imaging and reporting. As the only company to own the full workflow from biopsy to diagnosis, Leica Biosystems is uniquely positioned to break down the barriers between each step. The company’s mission of “Advancing Cancer Diagnostics, Improving Lives” is at the heart of its corporate culture.
Research Use Only and not for use in diagnostic procedures.
Contact:
Lauren Meinhardt
Communications & Brand Director
LBS.GlobalMarketing@leicabiosystems.com
SOURCE: Leica Biosystems
